Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $50.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 66.39% from the company’s current price.

A number of other equities analysts also recently issued reports on COLL. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $30.05 on Monday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market cap of $946.15 million, a price-to-earnings ratio of 12.95 and a beta of 0.99. The firm’s fifty day moving average price is $30.69 and its 200 day moving average price is $32.64. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. On average, sell-side analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock worth $3,243,594 over the last 90 days. 3.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Collegium Pharmaceutical by 1.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock valued at $522,000 after purchasing an additional 339 shares during the period. AlphaQuest LLC grew its position in shares of Collegium Pharmaceutical by 3.0% in the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after purchasing an additional 374 shares during the period. Foundry Partners LLC lifted its position in Collegium Pharmaceutical by 2.4% during the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $463,000 after buying an additional 381 shares during the period. Finally, Gallacher Capital Management LLC boosted its stake in Collegium Pharmaceutical by 3.3% in the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock worth $417,000 after buying an additional 470 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.